Solidly Positive Phase III Data Boost Keryx’ Struggling Iron Drug Auryxia
This article was originally published in The Pink Sheet Daily
Executive Summary
Keryx set to pursue expanded FDA labeling of its phosphate binder Auryxia to pre-dialysis patients with iron deficiency, a patient population already approved for treatment in Europe.